The Role of Serum IL-17 and IL-6 As Biomarkers of Disease Activity and Predictors of Remission in Patients with Lupus Nephritis
Overview
Biology
Affiliations
Aim: To determine the role of IL-17 and IL-6 in the pathogenesis of SLE as biomarkers of disease activity and predictors of remission and outcome of therapy in patients with active lupus nephritis.
Methods: The study was carried out on 72 SLE female patients and 70 sex- and age-matched normal healthy subjects as controls. SLE disease activity was assessed in all patients with (SLEDAI-2k scores). Plasma levels of IL-6, and IL-17 were measured by enzyme linked immunosorbent assay and their levels were correlated with clinical manifestations of the disease and (SLEDAI-2k). ROC curve analysis was performed to determine the validity of both cytokines in prediction of activity and remission of active lupus nephritis.
Results: SLE patients were found to have significantly higher levels of IL-17 (p<0.001) and IL-6 (p<0.001), in relation to normal subjects. Active group of patients had higher levels of both cytokines than the inactive one (P<0.001). Elevated serum levels of both cytokines were associated with active lupus nephritis, anemia and positively correlated with SLEDAI-2k scores (P=0.025 for IL-17 and P<0.001 for IL-6). There was a significant positive correlation between IL-6 and IL-17 serum concentrations during periods of disease activity (r=0.497, P=0.005) as well as during remission (r=0.662, P<0.001). ROC curve analysis for IL-6 and IL-17, as predictor of disease activity reviled, optimal cutoff level of 12.3 pg/ml and 19.7 pg/ml, with AUC=0.93, and 0.95, for both cytokines respectively, while as predictors of remission of active lupus nephritis, provide a cutoff value of IL-6 at 20.8 pg/ml, with AUC 0.80, and a cutoff value of IL-17 at 27.0 pg/ml, with AUC 0.82.
Conclusion: In conjunction with their major role in pathogenesis of SLE, baseline serum levels of IL-6 and IL-17 can be used as sensitive biomarkers for disease activity, as well as predictors of remission of lupus nephritis.
Park D, Joo Y, Nam E, Lee J, Bang S, Lee H Sci Rep. 2024; 14(1):31422.
PMID: 39733104 PMC: 11682382. DOI: 10.1038/s41598-024-83057-4.
Biomarkers Associated with Drugs for the Treatment of Lupus Nephritis.
Nie H, Chang S, Li Y, Li F Biomolecules. 2023; 13(11).
PMID: 38002282 PMC: 10669579. DOI: 10.3390/biom13111601.
Characterization of Serum Cytokine Profiles of Patients with Active Lupus Nephritis.
Rahme Z, Franco C, Cruciani C, Pettorossi F, Zaramella A, Realdon S Int J Mol Sci. 2023; 24(19).
PMID: 37834330 PMC: 10573765. DOI: 10.3390/ijms241914883.
Cytokines in Systemic Lupus Erythematosus-Focus on TNF-α and IL-17.
Richter P, Macovei L, Mihai I, Cardoneanu A, Burlui M, Rezus E Int J Mol Sci. 2023; 24(19).
PMID: 37833861 PMC: 10572174. DOI: 10.3390/ijms241914413.
Neves A, Viveiros L, Venturelli V, Isenberg D Res Rep Urol. 2023; 15:333-353.
PMID: 37456804 PMC: 10348374. DOI: 10.2147/RRU.S385836.